Cargando…
Deutetrabenazine in Tics Associated with Tourette Syndrome
BACKGROUND: Deutetrabenazine, an inhibitor of vesicular monoamine transporter type 2 (VMAT2) depletes presynaptic dopamine and is useful in the treatment of hyperkinetic movement disorders. This study explored the safety, tolerability, and preliminary efficacy of deutetrabenazine in adolescents with...
Autores principales: | Jankovic, Joseph, Jimenez-Shahed, Joohi, Budman, Cathy, Coffey, Barbara, Murphy, Tanya, Shprecher, David, Stamler, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Columbia University Libraries/Information Services
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133390/ https://www.ncbi.nlm.nih.gov/pubmed/27917309 http://dx.doi.org/10.7916/D8M32W3H |
Ejemplares similares
-
Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial
por: Coffey, Barbara, et al.
Publicado: (2021) -
Safety and Efficacy of Long‐Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open‐Label Extension Study
por: Jankovic, Joseph, et al.
Publicado: (2023) -
Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial
por: Jankovic, Joseph, et al.
Publicado: (2021) -
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia
por: Fernandez, Hubert H, et al.
Publicado: (2019) -
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study
por: Fernandez, Hubert H., et al.
Publicado: (2017)